Uterine Fibroids - Drug Pipeline Landscape, 2023

Uterine Fibroids - Drug Pipeline Landscape, 2023

Uterine fibroids are a common type of noncancerous tumor that can grow in and on your uterus. Uterine fibroids are found incidentally during a routine pelvic exam.

The causes of fibroids are unknown. Most fibroids happen in people of reproductive age. Possible causes include genetic changes, hormones, other growth factors and extracellular matrix.

Uterine fibroids patients may have symptoms, including excessive or painful menstruation, bloating, frequent urination, pain during intercourse, low back pain, constipation, chronic vaginal discharge and increased abdominal distention.

Uterine fibroids patients with symptoms may have to take the tests like ultrasound, lab tests and other imaging tests including MRI, hysterosonography, hysterosalpingography and hysteroscopy.

Treatment options for uterine fibroids can include over-the-counter (OTC) pain medications, gonadotropin-releasing hormone (GnRH) agonists, iron supplements, oral therapies and birth controls.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Uterine Fibroids treatment such as Linzagolix, TU-2670, and others. Key players involved in the development of therapies to treat Uterine Fibroids are Kissei Pharmaceutical Co Ltd, TiumBio Co Ltd, and others. One drug is under Phase III clinical trials and one drug are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Nov 2022, Tium Bio transferred the technology rights to China’s Hanso Pharmaceutical for China development of TU2670.

Report Highlights

Global Insight Service's, Uterine Fibroids - Drug Pipeline Landscape, 2023 report provides an overview of the Uterine fibroids pipeline drugs. This report covers detailed insights on Uterine Fibroids drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Uterine Fibroids pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.